3
Clinical Trials associated with H077 / Not yet recruitingPhase 3 A Randomized, Double-blind, Controlled, Non-inferiority Multicenter Phase III Clinical Study Evaluating the Efficacy and Safety of H077 Sustained-release Tablets Versus Silodosin Capsules in the Treatment of Benign Prostatic Hyperplasia
This is a randomized, double-blind, controlled, non-inferiority multicenter Phase III clinical study to evaluate the efficacy and safety of H077 sustained-release tablets versus silodosin capsules in treating benign prostatic hyperplasia.
H077缓释片在健康受试者中多次给药药代动力学的I期临床研究
[Translation] Phase I clinical study on the pharmacokinetics of H077 sustained-release tablets after repeated administration in healthy subjects
评价中国健康男性多次口服H077缓释片(1日1次)或赛洛多辛胶囊(1日2次)的药代动力学(PK)特征及安全性。
[Translation] To evaluate the pharmacokinetic (PK) characteristics and safety of multiple oral administration of H077 sustained-release tablets (once a day) or silodosin capsules (twice a day) in healthy Chinese men.
一项评价H077缓释片在健康受试者中单次给药药代动力学及食物影响的I期临床研究
[Translation] A Phase I clinical study to evaluate the single-dose pharmacokinetics and food effects of H077 extended-release tablets in healthy subjects
评价健康受试者口服H077缓释片单次给药的药代动力学(PK)特征。评价健康受试者高脂餐后和空腹条件下口服H077缓释片的PK特征。 评价健康受试者口服H077缓释片的安全性。
[Translation] To evaluate the pharmacokinetic (PK) characteristics of H077 sustained-release tablets after single oral administration in healthy subjects. To evaluate the PK characteristics of H077 sustained-release tablets after high-fat meal and under fasting conditions in healthy subjects. To evaluate the safety of H077 sustained-release tablets after oral administration in healthy subjects.
100 Clinical Results associated with H077
100 Translational Medicine associated with H077
100 Patents (Medical) associated with H077
100 Deals associated with H077